Developing and Commercializing Innovative Vaccines Protecting The World Against Infectious Diseases Utilizing Proven Innovative Adjuvant Technology COVID-19 Information and Resources During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]; maintaining our financial strength and stability; and supporting efforts to develop a COVID-19 vaccine. LEARN MORE. LEARN MORE ABOUT OUR PRODUCT Recent News NOV 18, 2021 Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference NOV 04, 2021 Dynavax Reports Third Quarter 2021 Financial Results VIEW ALL NEWS TERMS OF USE PRIVACY NOTICE © 2021 Dynavax Technologies. All rights reserved. Website Design: Hane Chow, Inc. US-20-00-00098

Skip to main navigation Analyst Coverage Dynavax Technologies Corporation is covered by the following analysts. FIRM ANALYST Cowen and Company, LLC Phil Nadeau, Ph.D. Evercore ISI Josh Schimmer Goldman Sachs & Co. LLC Madhu Kumar, Ph.D. H.C. Wainwright & Co., LLC Edward White William Blair & Company, L.L.C. Matt Phipps Dynavax Technologies Corporation is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Dynavax Technologies Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Dynavax Technologies Corporation or its management. Dynavax Technologies Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Email Alerts RSS Print Share Search ABOUT PRODUCT SCIENCE PORTFOLIO ONGOING STUDIES CAREERS CONTACT © 2021 Dynavax Technologies. All rights reserved. Website Design: Hane Chow, Inc.